Cereno Scientific announces that Aktiespararna initiates equity research coverage of company

Cereno Scientific (XSAT: CRNO B) today announced that Aktiespararna has been engaged by Cereno to produce regular, in-depth equity research reports on the company. The primary purpose is to raise the visibility of Cereno as well as enable investors and shareholders to develop an improved understanding of the business.

Aktiespararna is the world's largest member organization for private individuals who save in shares and funds with about 70,000 members. Analysguiden is Aktiespararna’s equity research service where investors can access analyses of the public companies that are covered by Aktiespararna without cost. The initial coverage report (in Swedish) is now published and available on Cereno’s website, www.cerenoscientific.com, as well as on Aktiespararna’s website, https://www.aktiespararna.se/analysguiden/Hitta-Bolag/cereno-scientific/cereno-scientific-ab.

For further information, please contact:

Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs named CS014 and CS585 targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.